SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.218 ^NOK	+2.83%		-0.91%	-93.27%

Apr. 18	Transcript : SoftOx Solutions AS - Special Call
Mar. 20	SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI

SOFTX; Fourth quarter 2023 report and investor deck used in MNOK 25 fund raising March 2024

March 20, 2024 at 02:31 am EDT

Please find attached the fourth quarter 2023 report and March 2024 investor
presentation deck used in connection with the ongoing MNOK 25 fund raising. The
company plan to call for a digital fourth quarter investor presentation soon
after Easter 2024. 

For any questions or interview requests, please contact: 
Geir Almås, Chair of SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Phone: Geir Almås: (+47) 977 59 071 

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com

Click here for more information

Latest news about SoftOx Solutions

Transcript : SoftOx Solutions AS - Special Call	Apr. 18
SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	Jan. 16	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	Jan. 10	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 31	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	23-09-18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	23-06-08	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	23-06-02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	23-03-27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	23-03-24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	23-01-09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	22-12-20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	22-12-19	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	22-12-19	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-12-14	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	22-10-19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	22-10-18	CI
SoftOx Solutions Signs $2 Million Convertible Loan Deal, Secures Refinancing	22-10-11	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding from Aubert Invest AS, Pro AS, Almhaug Bolig AS and other investors	22-10-10	CI
SoftOx Solutions AS Announces Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-10-03	CI

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-93.27%	9.94M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B